{"disease":{"id":"nasopharyngeal-carcinoma-by-ajcc-v8-stage","name":"nasopharyngeal carcinoma by ajcc v8 stage"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05858385","title":"Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","has_results":false},{"nct_id":"NCT06095154","title":"CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":474,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT05717790","title":"Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":288,"lead_sponsor_name":"Fourth Affiliated Hospital of Guangxi Medical University","has_results":false},{"nct_id":"NCT05513573","title":"Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT06509009","title":"Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}